<DOC>
	<DOC>NCT02397954</DOC>
	<brief_summary>The objectives of this study are to evaluate the safety and tolerability of Zimura® intravitreous injection in combination with anti-VEGF therapy in subjects with Idiopathic Polypoidal Choroidal Vasculopathy (IPCV).</brief_summary>
	<brief_title>A Study to Establish the Safety and Tolerability of Zimura® (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)</brief_title>
	<detailed_description>Treatment experienced (Prior treatment with anti-VEGF monotherapy of ≥8 injections in the previous twelve (12) months) subjects with IPCV will receive 3 monthly (Q4W) injections of Zimura® in combination with anti-VEGF therapy.</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Subjects of either gender aged ≥ 50 years Diagnosis of IPCV Treatmentexperienced defined as prior treatment with antiVEGF mono therapy of ≥ 8 injections in the previous twelve (12) months Any intraocular surgery or thermal laser within three (3) months of trial entry Any prior thermal laser in the macular region, regardless of indication Any ocular or periocular infection in the twelve (12) weeks prior to entry History of any of the following conditions or procedures in the study eye: Rhegmatogenous retinal detachment, pars plana vitrectomy, filtering surgery (e.g. trabeculectomy), glaucoma drainage device, corneal transplant Previous therapeutic radiation in the region of the study eye A diagnosis of diabetic retinopathy (presence of microaneurysms or any vasculopathy and/or leakage from retinal vasculature in a subject with diabetes mellitus)</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>idiopathic polypoidal choroidal vasculopathy</keyword>
	<keyword>IPCV</keyword>
	<keyword>Zimura®</keyword>
	<keyword>Avastin®</keyword>
	<keyword>Eylea®</keyword>
	<keyword>Lucentis®</keyword>
</DOC>